Big Data seems to be the solution to many of the world’s problems, if you believe the media stories that abound asserting its potential to address just about any problem out there. So, as our interest at the Focal Therapy Clinic is prostate cancer, we wanted to know if it is helping scientists and clinicians to better understand and treat prostate cancer, and if so how?
And before we even go there, we wanted to know what exactly is big data?
Google tells us that Big Data is a term that describes the large volume of data – both structured and unstructured – that inundates a business on a day-to-day basis. But it's not the amount of data that's important. It's what organizations do with the data that matters.
So what kind of large datasets do healthcare organisations generate, and what do they do with them?
Big data in healthcare describes massive volumes of information created by the adoption of digital technologies that collect patient information and help in managing hospital performance. Sources for big data include hospital records, medical records of patients, and results of medical tests. Clinical trials and biomedical research also generate a significant portion of big data relevant to public healthcare. Combined with large datasets on demography, for example, these health datasets can be analysed to give deep and evidence-based insight into a multitude of health-related questions.
In terms of questions related to prostate cancer, big data is helping to identify aggressive cancer, match the right treatment to the right man, and understand how cancer cells develop, leading to better diagnosis, better treatment and better prevention.
Prostate Cancer UK, with funding from the Movember Foundation is supporting research using big data – some examples of its application are:
- Building a database of genetic data from biopsy and blood samples
- Predict how gene activity is affected by prostate cancer treatments
- Develop computer models to understand why multiple prostate cancers appear together
- Disparities in the incidence of prostate cancer between different countries as well as unacceptable inequalities in prostate cancer survival rates across the EU. There is insufficient knowledge on risk factors for prostate cancer and on patient characteristics. This lack of knowledge means that prediction of which patients will have the best outcomes with specific treatments remains poor.
- A lack of meaningful engagement of all key stakeholders (including patients) in the processes which define the most important prostate cancer research questions that urgently need answering.
- Lack of effective implementation of knowledge gained in clinical practice (including knowledge informed by real-life data), with variability within and across European countries. This results in inequality in prostate cancer care, increased risk of short- and long-term harms to patients, as well as excess costs related to inappropriate management.